April 27, 2018 Drug Utilization Review Board
»
1. Call to order
1. Call to order
»
2. Approval of minutes from January 26, 2018 (vote required)
2. Approval of minutes from January 26, 2018 (vote required)
»
3. Elect vice-chair (vote required)
3. Elect vice-chair (vote required)
»
4. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the January 26, 2018, meeting
4. Old business: Report on Health and Human Services Commission decisions on acceptance of the Drug Utilization Review (DUR) Board recommendations from the January 26, 2018, meeting
»
5. New business:
Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL): » - a. Anti-allergens, oral b. Antibiotics, inhaled c. Anticoagulants d. Antidepressants, other e. Antidepressants, SSRIs f. Antidepressants, tricyclic g. Antihyperuricemics h. Antiparkinson agents i. Anxiolytics j. Beta-blockers k. Bile salts l. BPH treatments m. Bronchodilators, beta agonist n. COPD agents o. Cough and cold agents p. Erythropoiesis stimulating proteins q. Glucocorticoids, inhaled r. HAE treatments s. Hypoglycemics, SGLT2 t. Immune globulins u. Immunomodulators, atopic dermatitis v. Lincosamides/oxazolidinones/streptogramins w. Lipotropics, other x. Lipotropics, statins y. PAH agents, oral and inhaled z. Pancreatic enzymes aa. Sedative hypnotics ab. Urea cycle disorders, oral
Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL: a. Admelog Solostar Pen / Hypoglycemics, insulin and related agents b. Admelog Vial / Hypoglycemics, insulin and related agents c. Adzenys ER Suspension /Stimulants and related agents d. Bydureon Bcise / Hypoglycemics, incretin mimetics/enhancers e. Enbrel Cartridge / Cytokine and CAM antagonists f. Lyrica CR / Neuropathic pain g. Ozempic / Hypoglycemics, incretin mimetics/enhancers h. Qtern / Hypoglycemics, incretin mimetics/enhancers i. Retin-A Micro 0.06% Pump /Acne agents j. Solosec / Antibiotics, GI k. Vyzulta / Ophthalmics, glaucoma agents l. Ximino / Tetracyclines
5. New business: Public comment on drug classes and therapeutic and clinical drug reviews to be reviewed for the Medicaid Preferred Drug List (PDL): »
a. Anti-allergens, oral b. Antibiotics, inhaled
c. Anticoagulants
d. Antidepressants, other
e. Antidepressants, SSRIs
f. Antidepressants, tricyclic
g. Antihyperuricemics
h. Antiparkinson agents
i. Anxiolytics
j. Beta-blockers
k. Bile salts
l. BPH treatments
m. Bronchodilators, beta agonist
n. COPD agents
o. Cough and cold agents
p. Erythropoiesis stimulating proteins
q. Glucocorticoids, inhaled
r. HAE treatments
s. Hypoglycemics, SGLT2
t. Immune globulins
u. Immunomodulators, atopic dermatitis
v. Lincosamides/oxazolidinones/streptogramins
w. Lipotropics, other
x. Lipotropics, statins
y. PAH agents, oral and inhaled
z. Pancreatic enzymes
aa. Sedative hypnotics
ab. Urea cycle disorders, oral
Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
a. Admelog Solostar Pen / Hypoglycemics, insulin and related agents
b. Admelog Vial / Hypoglycemics, insulin and related agents
c. Adzenys ER Suspension /Stimulants and related agents
d. Bydureon Bcise / Hypoglycemics, incretin mimetics/enhancers
e. Enbrel Cartridge / Cytokine and CAM antagonists
f. Lyrica CR / Neuropathic pain
g. Ozempic / Hypoglycemics, incretin mimetics/enhancers
h. Qtern / Hypoglycemics, incretin mimetics/enhancers
i. Retin-A Micro 0.06% Pump /Acne agents
j. Solosec / Antibiotics, GI
k. Vyzulta / Ophthalmics, glaucoma agents
l. Ximino / Tetracyclines
»
6. Executive work session
Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
6. Executive work session Pursuant to Texas Government Code, Section 531.071, and in accordance with Texas Administrative Code, Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the DUR Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.
»
8. Announcements of drugs recommended for the Medicaid PDL (vote required)
8. Announcements of drugs recommended for the Medicaid PDL (vote required)
»
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC » - a. Report on recent retrospective DUR intervention: i. Asthma disease management ii. Bipolar disorder management iii. Migraine prevention and treatment iv. Psychotropic drugs in adults b. Report on recent retrospective DUR intervention outcomes: i. Diabetes disease management 2017 ii. Naloxone for opioid-related overdose c. Retrospective DUR proposals: (vote required) i. Diabetes disease management ii. Proton pump inhibitors iii. Rheumatoid arthritis disease management
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC »
a. Report on recent retrospective DUR intervention: i. Asthma disease management
ii. Bipolar disorder management
iii. Migraine prevention and treatment
iv. Psychotropic drugs in adults
b. Report on recent retrospective DUR intervention outcomes:
i. Diabetes disease management 2017
ii. Naloxone for opioid-related overdose
c. Retrospective DUR proposals: (vote required)
i. Diabetes disease management
ii. Proton pump inhibitors
iii. Rheumatoid arthritis disease management
»
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) » - a. Anxiolytics and Sedatives/Hypnotics - Buspirone criteria revision b. Cystic Fibrosis Agents - addition of Symdeko (Tezacaftor/Ivacaftor and Ivacaftor)
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required) »
a. Anxiolytics and Sedatives/Hypnotics - Buspirone criteria revision b. Cystic Fibrosis Agents - addition of Symdeko (Tezacaftor/Ivacaftor and Ivacaftor)
»
Items 11 - 13 » - 11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. Anticoagulants - oral, direct-acting (DOACs) b. Benzodiazepines - oral/rectal (nonsedative/hypnotic) c. Complement Inhibitor and Enzyme/Protein Replacement therapy d. HMG-CoA Reductase Inhibitors (Statins) e. Low Molecular weight heparins f. Nebulized bronchodilators 12. Adjourn 13. Next meeting date: July 27, 2018
Items 11 - 13 »
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required) a. Anticoagulants - oral, direct-acting (DOACs)
b. Benzodiazepines - oral/rectal (nonsedative/hypnotic)
c. Complement Inhibitor and Enzyme/Protein Replacement therapy
d. HMG-CoA Reductase Inhibitors (Statins)
e. Low Molecular weight heparins
f. Nebulized bronchodilators
12. Adjourn
13. Next meeting date: July 27, 2018
